Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent life-threatening human cancers and the leading cause of cancer-related mortality, with increased global incidence within the last decade. Identification of effective diagnostic and prognostic biomarkers would enable reliable risk stratification and efficient screening of high-risk patients, thereby facilitating clinical decision-making. Herein, we performed a comprehensive, robust DNA methylation analysis based on genome-wide DNA methylation profiling. We constructed a diagnostic signature with five DNA methylation markers, which precisely distinguished HCC patients from normal controls. Cox regression and LASSO analysis were applied to construct a prognostic signature with four DNA methylation markers. A one-to-one correlation analysis was carried out between genes of the whole genome and our prognostic signature. Exploration of the biological function and the role of the underlying significantly correlated genes was conducted. A mixed dataset of 463 HCC patients and 253 normal controls, derived from six independent datasets, was used to valid the diagnostic signature. Results showed a specificity of 96.84% and sensitivity of 96.77%. Class scores for the diagnostic signature were significantly different between normal controls, individuals with liver diseases, and HCC patients. The present signature has the potential to serve as a biomarker to monitor health in normal controls. Additionally, HCC patients were successfully separated into low-risk and high-risk groups by the prognostic signature, with a better prognosis for patients in the low-risk group. Kaplan-Meier and ROC analysis confirmed that the prognostic signature performed well. We found eight of the top ten genes to positively correlate with risk scores of the prognostic signature, and to be involved in cell cycle regulation. This eight-gene panel also served as a prognostic signature. The robust evidence presented in this study therefore demonstrates the effectiveness of the prognostic signature. In summary, we constructed diagnostic and prognostic signatures, which have potential for use in diagnosis, surveillance, and prognostic prediction for HCC patients. Eight genes that were significantly and positively correlated with the prognostic signature were strongly associated with cell cycle processes. Therefore, the prognostic signature can be used as a guide by which to measure responsiveness to cell-cycle-targeting agents.

Global Analysis of DNA Methylation in Hepatocellular Carcinoma Via a Whole-Genome Bisulfite Sequencing Approach

Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma

Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma.

Integrative Analysis of Epigenome and Transcriptome Data Reveals Aberrantly Methylated Promoters and Enhancers in Hepatocellular Carcinoma

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma

Contribution of DNA methylation to the risk of hepatitis C virus-associated hepatocellular carcinoma: A meta-analysis

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Meta-Analysis Of Dna Methylation Biomarkers In Hepatocellular Carcinoma

A New Approach to Evaluating Aberrant DNA Methylation Profiles in Hepatocellular Carcinoma as Potential Biomarkers

Aberrant Methylation Status of SPG20 Promoter in Hepatocellular Carcinoma: A Potential Tumor Metastasis Biomarker.

Additional File 7: Table S3. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

Identification and Analysis of DNA Methylation-Driven Signatures for Prognostic and Immune Microenvironments Evaluation in Hepatocellular Carcinoma

Revealing distinct DNA methylation patterns in hepatic carcinoma through high-throughput sequencing

Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis

The Effect of Key DNA Methylation in Different Regions on Gene Expression in Hepatocellular Carcinoma.

Exploring DNA Methylation Profiles Altered in Cryptogenic Hepatocellular Carcinomas by High-Throughput Targeted DNA Methylation Sequencing: A Preliminary Study for Cryptogenic Hepatocellular Carcinoma

An aberrant DNA methylation signature for predicting hepatocellular carcinoma

Construction of DNA methylation-based biomarkers for diagnosis of hepatocellular carcinoma.

Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

DNA methylation and gene expression profiling reveal potential association of retinol metabolism related genes with hepatocellular carcinoma development